NASDAQ
ICAD

icad inc

Medical Devices
Healthcare

Prices are adjusted according to historical splits.

icad inc Stock Price

Vitals

Today's Low:
$2.05
Today's High:
$2.2
Open Price:
$2.17
52W Low:
$1.05
52W High:
$3.97
Prev. Close:
$2.18
Volume:
204444

Company Statistics

Market Cap.:
$55.07 million
Book Value:
1.195
Revenue TTM:
$24.49 million
Operating Margin TTM:
-53.67%
Gross Profit TTM:
$20.11 million
Profit Margin:
-51.13%
Return on Assets TTM:
-15.92%
Return on Equity TTM:
-35.19%

Company Profile

icad inc had its IPO on 1986-12-03 under the ticker symbol ICAD.

The company operates in the Healthcare sector and Medical Devices industry. icad inc has a staff strength of 108 employees.

Stock update

Shares of icad inc opened at $2.17 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.05 - $2.2, and closed at $2.05.

This is a -5.96% slip from the previous day's closing price.

A total volume of 204,444 shares were traded at the close of the day’s session.

In the last one week, shares of icad inc have slipped by -13.5%.

icad inc's Key Ratios

icad inc has a market cap of $55.07 million, indicating a price to book ratio of 1.1149 and a price to sales ratio of 1.5566.

In the last 12-months icad inc’s revenue was $24.49 million with a gross profit of $20.11 million and an EBITDA of $-12663000. The EBITDA ratio measures icad inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, icad inc’s operating margin was -53.67% while its return on assets stood at -15.92% with a return of equity of -35.19%.

In Q2, icad inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 22.6%.

icad inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
-0.56

Its diluted EPS in the last 12-months stands at $-0.52 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.56. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into icad inc’s profitability.

icad inc stock is trading at a EV to sales ratio of 0.6966 and a EV to EBITDA ratio of -1.44. Its price to sales ratio in the trailing 12-months stood at 1.5566.

icad inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$44.83 million
Total Liabilities
$11.89 million
Operating Cash Flow
$0
Capital Expenditure
$221000
Dividend Payout Ratio
0%

icad inc ended 2024 with $44.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $44.83 million while shareholder equity stood at $30.17 million.

icad inc ended 2024 with $0 in deferred long-term liabilities, $11.89 million in other current liabilities, 254000.00 in common stock, $-272364000.00 in retained earnings and $8.36 million in goodwill. Its cash balance stood at $19.04 million and cash and short-term investments were $19.04 million. The company’s total short-term debt was $644,000 while long-term debt stood at $0.

icad inc’s total current assets stands at $31.34 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.75 million compared to accounts payable of $857000.00 and inventory worth $4.25 million.

In 2024, icad inc's operating cash flow was $0 while its capital expenditure stood at $221000.

Comparatively, icad inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.05
52-Week High
$3.97
52-Week Low
$1.05
Analyst Target Price
$4.88

icad inc stock is currently trading at $2.05 per share. It touched a 52-week high of $3.97 and a 52-week low of $3.97. Analysts tracking the stock have a 12-month average target price of $4.88.

Its 50-day moving average was $2.48 and 200-day moving average was $1.9 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.

Around 607% of the company’s stock are held by insiders while 3687.8% are held by institutions.

Frequently Asked Questions About icad inc

The stock symbol (also called stock or share ticker) of icad inc is ICAD

The IPO of icad inc took place on 1986-12-03

Similar Industry Stocks (Medical Devices)

Last Price
Chg
Chg%
$119.1
-19.6
-14.13%
$1.69
-0.03
-1.74%
$155.25
-9.25
-5.62%
$842.6
-35.25
-4.02%
$0.05
0
+8.09%
$0.02
0
+0.5%
$3.26
-0.05
-1.51%
$0.27
0
+0.75%
$21.77
0.07
+0.32%
$53.4
-3.7
-6.48%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company’s breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and PowerLook Density Assessment provides automated, consistent, and standardized breast density assessments. The company also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a clinical decision support tool that provides breast cancer risk estimation based on a screening mammogram; and VeraLook, a solution designed to support detection of colonic polyps in conjunction with Computed Tomography Colonography. In addition, it offers Xoft Axxent electronic brachytherapy systems for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Address

98 Spit Brook Road, Nashua, NH, United States, 03062